JP2015521632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521632A5 JP2015521632A5 JP2015518732A JP2015518732A JP2015521632A5 JP 2015521632 A5 JP2015521632 A5 JP 2015521632A5 JP 2015518732 A JP2015518732 A JP 2015518732A JP 2015518732 A JP2015518732 A JP 2015518732A JP 2015521632 A5 JP2015521632 A5 JP 2015521632A5
- Authority
- JP
- Japan
- Prior art keywords
- apc
- use according
- skin
- psoriasis
- motomeko
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000004681 Psoriasis Diseases 0.000 claims 9
- 210000003491 skin Anatomy 0.000 claims 8
- 208000017520 skin disease Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 210000002510 keratinocyte Anatomy 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 206010037575 Pustular psoriasis Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 101800004937 Protein C Proteins 0.000 claims 3
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 3
- 101800001700 Saposin-D Proteins 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 229960000856 protein c Drugs 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000004888 barrier function Effects 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012902874 | 2012-07-04 | ||
| AU2012902874A AU2012902874A0 (en) | 2012-07-04 | Treatment of inflammatory skin disorders | |
| PCT/AU2013/000729 WO2014005183A1 (en) | 2012-07-04 | 2013-07-04 | Treatment of inflammatory skin disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521632A JP2015521632A (ja) | 2015-07-30 |
| JP2015521632A5 true JP2015521632A5 (enExample) | 2016-08-25 |
| JP6273272B2 JP6273272B2 (ja) | 2018-01-31 |
Family
ID=49881162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518732A Active JP6273272B2 (ja) | 2012-07-04 | 2013-07-04 | 炎症性皮膚障害の治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150150954A1 (enExample) |
| EP (1) | EP2869833B1 (enExample) |
| JP (1) | JP6273272B2 (enExample) |
| KR (1) | KR102068010B1 (enExample) |
| CN (1) | CN104394883B (enExample) |
| AU (1) | AU2013286812B2 (enExample) |
| BR (1) | BR112015000051A2 (enExample) |
| CA (1) | CA2877745C (enExample) |
| ES (1) | ES2676422T3 (enExample) |
| IN (1) | IN2014DN11181A (enExample) |
| RU (1) | RU2662564C2 (enExample) |
| WO (1) | WO2014005183A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6273272B2 (ja) * | 2012-07-04 | 2018-01-31 | ジージー バイオテック エルエルシー | 炎症性皮膚障害の治療 |
| DK3137102T3 (da) | 2014-04-16 | 2021-10-11 | Zz Biotech Llc | Apc til anvendelse til behandling af unormal kutan ardannelse |
| ES2890623T3 (es) | 2014-04-16 | 2022-01-20 | Zz Biotech Llc | Uso del análogo de APC para curar heridas |
| WO2018068759A1 (zh) | 2016-10-14 | 2018-04-19 | 江苏恒瑞医药股份有限公司 | 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用 |
| EP3801028A4 (en) | 2018-05-30 | 2022-04-13 | Direct Biologics LLC | A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use |
| WO2020000059A1 (en) * | 2018-06-28 | 2020-01-02 | Novapep Pty Ltd | Inflammatory skin disorder treatment |
| CN109337974B (zh) * | 2018-12-14 | 2022-01-25 | 北京蛋白质组研究中心 | 一种检测银屑病的诊断标志物的试剂及其应用 |
| AU2019416339A1 (en) * | 2018-12-26 | 2021-07-22 | Direct Biologics Llc | Methods and compositions for treating skin and hair disorders |
| IL320107A (en) | 2019-02-07 | 2025-06-01 | Direct Biologics Llc | Method for treating osteoarthritis with a combination of mesenchymal stem cell exosomes, synovial mesencymal stem cells, and scaffolds |
| RU2704322C1 (ru) * | 2019-06-11 | 2019-10-28 | Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Крем с секретомом мультипотентных мезенхимальных стромальных клеток для коррекции псориазиформного воспаления в эксперименте |
| WO2021011935A1 (en) | 2019-07-18 | 2021-01-21 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| MX2022013301A (es) | 2020-04-22 | 2023-02-14 | Direct Biologics Llc | Métodos y composiciones para tratar las afecciones inflamatorias asociadas con una enfermedad infecciosa. |
| WO2025226276A1 (en) | 2024-04-25 | 2025-10-30 | Direct Biologics, Llc | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US5516650A (en) | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| US4959318A (en) | 1985-06-27 | 1990-09-25 | Zymogenetics, Inc. | Expression of protein C |
| EP0380508A4 (en) | 1987-05-18 | 1991-04-03 | Integrated Genetics, Inc. | Improved protein c molecules and method for making and activating same |
| US5084274A (en) | 1987-11-17 | 1992-01-28 | Scripps Clinic And Research Foundation | Inhibition of arterial thrombotic occlusion or thromboembolism |
| US4981952A (en) | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5093117A (en) | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| AT402260B (de) | 1990-08-16 | 1997-03-25 | Immuno Ag | Protein c-hältige pharmazeutische präparation |
| US5571786A (en) | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
| AT397615B (de) | 1991-05-14 | 1994-05-25 | Immuno Ag | Arzneimittel enthaltend protein c |
| WO1993009807A1 (en) | 1991-11-18 | 1993-05-27 | The Scripps Research Institute | Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels |
| MY110664A (en) | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| DE4239150A1 (de) | 1992-11-20 | 1994-05-26 | Thomae Gmbh Dr K | O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung |
| JP3043558B2 (ja) | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインｃ調製物及びその製法 |
| WO1995030429A1 (en) | 1994-05-04 | 1995-11-16 | Board Of Trustees Of The University Of Arkansas | Novel ophthalmologic uses of protein c |
| ZA983497B (en) | 1997-04-28 | 1999-10-25 | Lilly Co Eli | Activated protein c formulations. |
| HUP0001237A3 (en) | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| WO2001056532A2 (en) | 2000-02-04 | 2001-08-09 | The Scripps Research Institute | Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc) |
| WO2001059084A1 (en) | 2000-02-11 | 2001-08-16 | Eli Lilly And Company | Protein c derivatives |
| WO2001072328A2 (en) | 2000-03-28 | 2001-10-04 | Eli Lilly And Company | Methods of treating diseases with activated protein c |
| AU1038802A (en) | 2000-10-18 | 2002-04-29 | Maxygen Aps | Protein c or activated protein c-like molecules |
| ATE550073T1 (de) * | 2001-06-13 | 2012-04-15 | Univ Sydney | Protein c für die wundheilung |
| AU2003275948A1 (en) * | 2002-11-06 | 2004-06-07 | Novo Nordisk A/S | Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides |
| ATE337003T1 (de) | 2003-04-28 | 2006-09-15 | Biofrontera Bioscience Gmbh | Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis |
| US9192657B2 (en) | 2003-07-08 | 2015-11-24 | The Scripps Research Institute | Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity |
| EP1651252B1 (en) | 2003-07-08 | 2014-11-26 | The Scripps Research Institute | Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity |
| EP1688161A1 (en) * | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| US20080293631A1 (en) * | 2005-01-07 | 2008-11-27 | Christopher John Jackson | Treatment for Autoimmune and Inflammatory Conditions |
| US20070224150A1 (en) * | 2005-03-24 | 2007-09-27 | Yongji Chung | Growth factor for hair and skin treatment |
| ZA200800251B (en) | 2005-06-24 | 2009-04-29 | Drugrecure Aps | Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track |
| US7345178B2 (en) * | 2005-08-04 | 2008-03-18 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
| GR1005700B (el) * | 2006-09-01 | 2007-10-22 | (40%) ����� �������� | Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα |
| EP2078074A4 (en) | 2006-10-31 | 2011-09-28 | Scripps Research Inst | DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY |
| GB0724231D0 (en) | 2007-12-12 | 2008-01-30 | Renono Ltd | Methods for inhibiting scarring |
| ES2316312B1 (es) * | 2008-06-20 | 2010-02-08 | Ignacio Umbert Millet | Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas. |
| EP2157176A1 (en) * | 2008-08-20 | 2010-02-24 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Protein C Variants |
| JP2012522762A (ja) * | 2009-04-01 | 2012-09-27 | ザ メディカル リサーチ， インフラストラクチャー， アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター | ケラチノサイトの増殖および分化を調節する方法 |
| CN101912450A (zh) * | 2010-09-01 | 2010-12-15 | 吴业刚 | 一种治疗脚气皮炎的中西药组合物及其制备方法 |
| JP6273272B2 (ja) * | 2012-07-04 | 2018-01-31 | ジージー バイオテック エルエルシー | 炎症性皮膚障害の治療 |
| ES2890623T3 (es) * | 2014-04-16 | 2022-01-20 | Zz Biotech Llc | Uso del análogo de APC para curar heridas |
| DK3137102T3 (da) * | 2014-04-16 | 2021-10-11 | Zz Biotech Llc | Apc til anvendelse til behandling af unormal kutan ardannelse |
| WO2020000059A1 (en) * | 2018-06-28 | 2020-01-02 | Novapep Pty Ltd | Inflammatory skin disorder treatment |
-
2013
- 2013-07-04 JP JP2015518732A patent/JP6273272B2/ja active Active
- 2013-07-04 WO PCT/AU2013/000729 patent/WO2014005183A1/en not_active Ceased
- 2013-07-04 IN IN11181DEN2014 patent/IN2014DN11181A/en unknown
- 2013-07-04 EP EP13812528.1A patent/EP2869833B1/en active Active
- 2013-07-04 BR BR112015000051A patent/BR112015000051A2/pt not_active Application Discontinuation
- 2013-07-04 ES ES13812528.1T patent/ES2676422T3/es active Active
- 2013-07-04 CN CN201380034024.2A patent/CN104394883B/zh active Active
- 2013-07-04 RU RU2015103510A patent/RU2662564C2/ru active
- 2013-07-04 KR KR1020157002889A patent/KR102068010B1/ko active Active
- 2013-07-04 AU AU2013286812A patent/AU2013286812B2/en active Active
- 2013-07-04 CA CA2877745A patent/CA2877745C/en active Active
- 2013-07-04 US US14/409,215 patent/US20150150954A1/en not_active Abandoned
-
2016
- 2016-11-30 US US15/365,567 patent/US20170080062A1/en not_active Abandoned
-
2020
- 2020-05-21 US US16/880,243 patent/US11617785B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10695287B2 (en) | AMPK agonist topical medication for the treatment of certain specific medical conditions, methods of use thereof and wound dressing employing the same | |
| WO2010070675A3 (en) | Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof | |
| RU2015103510A (ru) | Лечение воспалительных заболеваний кожи | |
| MX2010000927A (es) | Uso de analogos y derivados de la vitamina k para el tratamiento de transtornos y condiciones de enfermedad en humanos. | |
| CA3006294A1 (en) | Combinations of rapamycin and metformin for the treatment of joint and skin diseases | |
| WO2015066647A3 (en) | Ionic liquids for transdermal drug delivery | |
| BR112015005339A8 (pt) | uso de óleo de semente de fruta milagrosa como um ingrediente ativo | |
| EP4552650A3 (en) | Methods and compositions for treatment of skin | |
| RU2007118663A (ru) | Способ применения адапалена при поддерживающей терапии угревой сыпи | |
| SA519410993B1 (ar) | النشاط المضاد للبكتيريا لأوليجو سكاريد من جالاكتو وزيليتول في العلاجات الجلدية | |
| CR20160277A (es) | Piperidinil tetrahidroquinolinas sustituidas | |
| JP2020525460A5 (enExample) | ||
| RU2007101538A (ru) | Применение фармацевтической композиции, содержащей кальцитриол и пропионат клобетазола, для лечения псориаза | |
| RU2011148355A (ru) | Применение аллопуринола для ладонно-родошвенного синдрома | |
| CA2566776A1 (en) | Method for ameliorating an inflammatory skin condition | |
| WO2017129108A1 (zh) | 一种用于治疗皮肤病的硅凝胶 | |
| JP2014532694A5 (enExample) | ||
| WO2014070696A3 (en) | Treatment of chronic dermal inflammatory with norketotifen | |
| BRPI0417116A (pt) | usos de uma quantidade eficaz de ondansetron e composição para tratamento tópico de uma inflamação | |
| BR112014005966A2 (pt) | composições para o tratamento de úlceras periféricas de várias origens | |
| WO2016063265A3 (pt) | Formulação tópica para o tratamento de infeções na pele ou mucosas, método de preparação e seus usos | |
| WO2010057117A3 (en) | Topical transdermal drug delivery compositions | |
| BRPI0415225A (pt) | composições tópicas compreendendo telmesteìna para o tratamento de distúrbios dermatológicos | |
| AR108793A1 (es) | Composiciones que comprenden timolol y un agente antiinflamatorio | |
| AU2017259411A1 (en) | Treating activated dermal conditions with agents that target energy metabolism |